...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Annual Financial Reporting
Reply New Message
Prev Message Back To Forum Threaded View Next Message

At first I was going by the 45 days rule for interim reporting . But Zenith may not fall under it being on the OTC.

Anxious to know HL's intention. Renew or convert. Tic Toc!

 

Koo

2 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply